Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lyzyme
- Development stage
- Unknown
- Lead developer
- Stadchem
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Lyzyme is an oral digestive aid syrup developed and marketed by Stadchem. It is a fixed-dose combination of two key digestive enzymes: fungal diastase (alpha-amylase) and pepsin. Fungal diastase is a starch-degrading enzyme that hydrolyzes complex carbohydrates into simpler sugars like maltose, facilitating easier absorption. Pepsin is a proteolytic enzyme that cleaves dietary proteins into smaller peptides within the acidic environment of the stomach. Together, these enzymes supplement the body's natural digestive capacity to relieve symptoms of indigestion, dyspepsia, flatulence, bloating, and loss of appetite.
- Brand names
- Lyzyme
- Other names
- diastase + pepsinfungal diastase + pepsin
Beyond the preview
Go deeper on Lyzyme.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lyzyme.